BR9909267A - C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos - Google Patents

C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos

Info

Publication number
BR9909267A
BR9909267A BR9909267-0A BR9909267A BR9909267A BR 9909267 A BR9909267 A BR 9909267A BR 9909267 A BR9909267 A BR 9909267A BR 9909267 A BR9909267 A BR 9909267A
Authority
BR
Brazil
Prior art keywords
compounds
useful
glaucoma
oxymyl
medications
Prior art date
Application number
BR9909267-0A
Other languages
English (en)
Inventor
Mitchell Anthony Delong
Jack Snyder Amburgey Jr
John August Wos
Biswanath De
David Lindsey Soper
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9909267A publication Critical patent/BR9909267A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • C07D307/42Singly bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08Hydroxylamino compounds or their ethers or esters
    • C07C239/18Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/44Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"C11 OXIMILA E PROSTAGLANDINAS HIDROXILAMINO úTEIS COMO MEDICAMENTOS"<D>. A invenção provê novos análogos de prostaglandina. Especificamente, a presente invenção refere-se aos compostos possuindo uma estrutura de acordo com a fórmula (I): onde: R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, W, X, Z, a, b e p são definidos a seguir. A invenção também inclui isómeros ópticos, diastereómeros e enantiómeros da fórmula acima, e sais farmaceuticamente aceitáveis, amidos biohidrolizáveis, ésteres e imidas dos mesmos. Os compostos da presente invenção são úteis para o tratamento de várias doenças e condições, tais como, distúrbios ósseos e glaucoma. Conseq³entemente, a invenção provê, adicionalmente, composições farmacêuticas compreendendo estes compostos. A invenção ainda provê processos para tratamento de distúrbios ósseos e glaucoma usando estes compostos ou as composições que contém os mesmos.
BR9909267-0A 1998-03-31 1999-03-22 C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos BR9909267A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8007598P 1998-03-31 1998-03-31
PCT/IB1999/000478 WO1999050241A1 (en) 1998-03-31 1999-03-22 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments

Publications (1)

Publication Number Publication Date
BR9909267A true BR9909267A (pt) 2000-11-21

Family

ID=22155104

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909267-0A BR9909267A (pt) 1998-03-31 1999-03-22 C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos

Country Status (23)

Country Link
US (1) US6410780B1 (pt)
EP (1) EP1082299B1 (pt)
JP (1) JP2002509915A (pt)
KR (1) KR20010042286A (pt)
CN (1) CN1295560A (pt)
AR (1) AR020063A1 (pt)
AT (1) ATE270272T1 (pt)
AU (1) AU749796B2 (pt)
BR (1) BR9909267A (pt)
CA (1) CA2324343C (pt)
DE (1) DE69918433T2 (pt)
ES (1) ES2223180T3 (pt)
HU (1) HUP0102789A2 (pt)
ID (1) ID26699A (pt)
IL (1) IL138446A0 (pt)
NO (1) NO20004904L (pt)
NZ (1) NZ506853A (pt)
PE (1) PE20000350A1 (pt)
PL (1) PL343113A1 (pt)
SK (1) SK14732000A3 (pt)
TR (1) TR200002808T2 (pt)
WO (1) WO1999050241A1 (pt)
ZA (1) ZA992393B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20060135609A1 (en) 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CN102101835B (zh) * 2009-12-16 2015-07-22 武汉启瑞药业有限公司 前列腺素衍生物及其中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776938A (en) 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3636120A (en) * 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
US4011262A (en) 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US4024179A (en) 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
DE2460990A1 (de) 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
JPH0222226A (ja) * 1988-07-12 1990-01-25 Ono Pharmaceut Co Ltd Pgd類似化合物を有効成分として含有する骨疾患治療剤
JP2721414B2 (ja) 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体

Also Published As

Publication number Publication date
SK14732000A3 (sk) 2001-04-09
ZA992393B (en) 1999-09-03
EP1082299A1 (en) 2001-03-14
KR20010042286A (ko) 2001-05-25
TR200002808T2 (tr) 2001-01-22
PE20000350A1 (es) 2000-06-22
NO20004904D0 (no) 2000-09-29
ID26699A (id) 2001-02-01
PL343113A1 (en) 2001-07-30
ATE270272T1 (de) 2004-07-15
ES2223180T3 (es) 2005-02-16
WO1999050241A1 (en) 1999-10-07
CA2324343C (en) 2005-05-31
NO20004904L (no) 2000-11-29
JP2002509915A (ja) 2002-04-02
EP1082299B1 (en) 2004-06-30
AR020063A1 (es) 2002-04-10
CN1295560A (zh) 2001-05-16
CA2324343A1 (en) 1999-10-07
AU749796B2 (en) 2002-07-04
IL138446A0 (en) 2001-10-31
HUP0102789A2 (hu) 2001-12-28
US6410780B1 (en) 2002-06-25
AU3270199A (en) 1999-10-18
DE69918433D1 (de) 2004-08-05
DE69918433T2 (de) 2005-09-01
NZ506853A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
BR9811774A (pt) Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
BR9909620A (pt) Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo
BR9909267A (pt) C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR9914696A (pt) Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica
AR009990A1 (es) Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen
BR9713182A (pt) Amidas de ácido fosfìnico como inibidores de metalo protease de matriz
BR9912969A (pt) Composto, composição farmacêutica, método para o tratamento dos distúrbios neurológicos associados com a produção de b-amilóide, método para o tratamento da doença de alzheimer associada com a produção de b-amilóide, método para o tratamento dos distúrbios neurológicos associados com a produção de b-amilóide e método para inibir a atividade de y-secretase
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
BRPI0407055A (pt) Derivados de isotiazol
EA200100396A1 (ru) Новые макролидные антибиотики
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
BR0009244A (pt) Inibidores de metaloprotease di-hétero substituìdos
BR0008716A (pt) Inibidores de metaloprotease contendo alquenil ou alquinil
NO20020523L (no) Nye 2-dekarboksy-2-fosfinikoprostaglandin F-analoger
ATE312815T1 (de) Neue verbindungen
AU614003B2 (en) Thiol ketone (or aldehyde) derivatives and pharmaceutical preparations containing them
BR9909268A (pt) C11 oximil e hidroxilamino prostaglandinas úteis como agonistas de fp
BR9713850A (pt) Composto, composição farmacêutica, processos para profilaxia ou tratamento de infecção e de doenças, para diminuir concentrações no plasma de qualquer um ou de ambos tnf-. e o;-1 de qualquer um ou de ambos il-6 e il-8, para profilaxia ou tratamento da doença diabetes e de um distúrbio da dor em um mamìfero, para dimunuir a produção de prostaglandinas em um mamìfero, e, para dimuir a atividade da enzima ciclooxigenase em um mamìfero.
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.